Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
Himal Lal, Anthony L Cunningham, Olivier Godeaux...
https://pubmed.ncbi.nlm.nih.gov/25916341/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-11-03
225
Participants Needed
1
Research Sites
34 weeks
Total Duration
Researchers are evaluating the safety and immune response of the Shingrix vaccine in people with HIV aged 18 years and older, as well as in healthy adults aged 50 years and older. The study aims to understand how the vaccine affects immune function in these groups, particularly focusing on differences in immune response based on CD4 cell counts and age. This phase 12 open-label trial includes monitoring of adverse events and comparison between people with HIV and healthy volunteers. Participants will receive two doses of Shingrix vaccine administered by intramuscular injection in the upper arm, spaced about 2 months apart. Blood samples will be collected before each dose and at follow-up visits at 3 and 12 months after the first dose. Additional procedures include rectal swabs for microbiome analysis and optional apheresis to collect white blood cells. Participants will also use a 28-day memory tool to record symptoms and participate in up to four phone calls discussing vaccine side effects. Participants will attend at least four clinic visits over one year for physical exams, blood and urine tests, and safety monitoring. Researchers will evaluate immune responses through antibody measurements and T-cell assays, as well as track safety by assessing adverse events. The study includes ongoing monitoring of viral load in people with HIV and collects detailed health information to correlate with vaccine response. Total participation lasts about one year with follow-up visits to assess long-term effects.
CONDITIONS
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
M
Maura M Manion, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Shingrix (in trial) | Standard RZV (current care) |
|---|---|---|
| What it is | A single‑group study administering Shingrix, a recombinant adjuvanted herpes zoster vaccine, via intramuscular injection to people with HIV (by CD4 strata) and healthy adults | Two‑dose recombinant zoster vaccine (RZV) regimen recommended by CDC/ACIP for immunocompromised adults ≥19 years and immunocompetent adults ≥50 years |
| Role in trial | Investigational intervention administered to all enrolled participants | Not used in this trial but represents current prevention practice |
| Primary use | Prevent and measure immune response to herpes zoster in people with HIV and healthy volunteers | Prevent herpes zoster in immunocompromised and older adults per established guidelines |
| Administration | Shingrix given as intramuscular injection of 0.5 mL in the upper‑arm deltoid, reconstituted from lyophilized antigen with AS01B adjuvant | Two intramuscular doses of RZV given per schedule (typically 2–6 months apart for immunocompetent; possibly 1–2 months in immunocompromised) |
| Evidence status | Immunogenicity being measured through antibody fold‑change in this population; results not yet posted | RZV efficacy demonstrated in older adults in pivotal trials; generally effective at preventing shingles |
| Important risks | Grade 3/4 local and systemic adverse reactions will be assessed but not yet reported | Shingrix has known local and systemic reactogenicity based on older adult trials |
| Limitations | Open‑label, single‑group design with no control arm limits direct efficacy comparison | Evidence from general older adult population; immunocompromised HIV populations may respond differently |
| Patient impact | Not yet established; immunogenicity outcomes pending | Proven benefit in preventing shingles in older adults |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility, including physical exams, blood and urine tests, and HIV status confirmation.
1 visit
Duration - 12 months
Participants receive two doses of Shingrix vaccine about 2 months apart, with blood collection before each dose. Follow-up visits occur at 3 and 12 months to monitor immune response and safety. Additional procedures may include rectal swabs and optional apheresis.
At least 4 clinic visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Himal Lal, Anthony L Cunningham, Olivier Godeaux...
https://pubmed.ncbi.nlm.nih.gov/25916341/Elchonon M Berkowitz, Graeme Moyle, Hans-Jürgen Stellbrink...
https://pubmed.ncbi.nlm.nih.gov/25371534/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor